Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to novel medica ⁇ ments containing GLP-l(7-37) , GLP-1(7-36)amide or analogues or functional derivatives thereof and a phospholipid, and to a method for preparing such medicaments.
• Glucagon-li e peptide-1 is a peptide sequence found in the C-terminal portion of mammalian proglucagon.
• GLP-1(1-36)amide like gluca- gon, stimulates insulin release from isolated precultured rat pancreatic islets in the presence of glucose in a dose-dependent manner (Schmidt, .E. et al. Diabetolo ia 28 (1985) 704-7) .
• This finding suggests that GLP-1(1-36) amide and related peptides might be useful in the treatment of type 2 diabetes.
• GIP glucose dependent insulinotropic peptide
• 87/06941 (to The General Hospital Corporation) relates to a peptide fragment which comprises GLP-l(7-37) and functional derivatives thereof and to its use as an insulinotropic agent.
• 90/11296 (to The General Hospital Corporation) relates to a peptide fragment which comprises GLP-l(7-36) and functional derivatives thereof and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-l(l-36) or GLP-
• the present invention is based on the fact that when GLP-1 related peptides are administered in a formula ⁇ tion comprising certain phospholipids, a very favourable absorption profile is found. Also, the phospholipids exert a stabilizing effect on the peptides.
• the present inven ⁇ tion relates to a medicament for intranasal administration of a peptide fragment of formula I:
• X is NH 2 or Gly-OH, or analogues or functional derivatives thereof, which medicament further comprises at least one phospholipid of the general formula II: (0) (OH) -OR ' ' '
• R 1 and 1 ' are the same or different each repre ⁇ senting hydrogen, alkyl, alkenyl, alkanoyl, alkenoyl, alka- dienoyl, alkatrienoyl or alkatetraenoyl containing not more than 14 carbon atoms in each group, with the proviso that R 1 and R 1 ' are not hydrogen at the same time, and R" 1 is 2-
• the invention relates to a medicament comprising GLP-1(7-36)amide.
• the invention relates to a medicament comprising GLP-l(7-37). In a further preferred embodiment, the invention relates to a medicament comprising fragments of GLP-l(7-37).
• the invention relates to a medicament comprising functional derivatives of fragments of GLP-l(7-37). In a further preferred embodiment, the invention relates to a medicament comprising analogues of GLP-1(7-37) .
• the invention relates to a medicament comprising functional derivatives of analogues of GLP-l(7-37).
• the invention relates to a medicament comprising a phospholipid of formula II wherein R , n is 2-(trimethylammonio)ethyl.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R 1 is alkyl having from 4 to 12 carbon atoms. In a further preferred embodiment, the invention relates to a medicament comprising a phospholipid of formula II wherein R' is alkanoyl having from 4 to 12 carbon atoms.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R 1 is decanoyl.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R' is hydrogen, with the proviso that R ! ' is different from hydrogen.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R 1 ' is alkyl having from 4 to 12 carbon atoms.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R' ' is alkanoyl having from 4 to 12 carbon atoms.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R 1 * is decanoyl.
• the invention relates to a medicament comprising a phospholipid of formula II wherein R 1 ' is hydrogen, with the proviso that R 1 is different from hydrogen.
• the invention relates to a medicament comprising didecanoyl L- ⁇ -phos- phatidylcholine.
• the invention relates to a medicament comprising a solid diluent.
• the invention relates to a solid medicament comprising from 0.01 to 75 % (W/W), preferably from 0.1 to 50 % (W/W) , more preferred from 0.5 to 25 % (W/W) of a peptide of formula I or ana ⁇ logues or functional derivatives thereof.
• the invention relates to a solid medicament comprising from 10 to 99 % (W/W) , preferably from 10 to 80 % (W/W) , more preferred from 25 to 60 % (W/W) of a phospholipid of formula II.
• the invention relates to a medicament comprising a liquid diluent.
• the invention relates to a liquid medicament comprising from 0.0005 to 10 % (W/W), preferably from 0.001 to 5 % (W/W), more preferred from 0.01 to 5 % (W/W) of a peptide of formula I or ana ⁇ logues or functional derivatives thereof.
• the invention relates to a liquid medicament comprising from 0.01 to 20 % (W/W) , preferably from 0.05 to 10 % (W/W) , more preferred from 0.1 to 5 % (W/W) of a phospholipid of formula II.
• the invention relates to a method of making a medicament for intranasal administration of a peptide fragment of formula I:
• X is NH 2 or Gly-OH, and analogues and functional derivatives thereof and further comprising at least one phospholipid of the general formula II:
• R 1 and R 1 * are the same or different each repre ⁇ senting hydrogen, alkyl, alkenyl, alkanoyl, alkenoyl, alka- dienoyl, alkatrienoyl or alkatetraenoyl containing not more than 14 carbon atoms in each group, with the proviso that R 1 and R' • are not hydrogen at the same time, and R ⁇ n is 2- (trimethylammonio)ethyl, 2-aminoethyl or 2,3-dihydroxy- propyl, which method comprises mixing the required amounts of the peptide fragment of formula I and at least one phos- phopholipid of formula II, optionally in a solid or in a liquid diluent, and optionally further adding pH buffering agents, osmotic pressure controlling agents, preservatives or other ancillary agents.
• the invention relates to a medicament for intranasal administration of a peptide fragment of formula I:
• X is NH 2 or Gly-OH, or analogues or functional derivatives thereof, characterized in that it further com ⁇ prises at least one phospholipid of the general formula II:
• R 1 and R' ' are the same or different each repre- senting hydrogen, alkyl, alkenyl, alkanoyl, alkenoyl, alka- dienoyl, alkatrienoyl or alkatetraenoyl containing not more than 14 carbon atoms in each group, with the proviso that R 1 and R 1 • are not hydrogen at the same time, and R" 1 is 2- (trimethylammonio)ethyl, 2-aminoethyl or 2,3-dihydroxypropyl when used as an insuliontropic agent in the treatment of diabetes.
• analogues of GLPrl(7-37) means peptides which differ from GLP-l(7-37) in that at least one of the amino acid residues of GLP-1(7-37) indepen- dently have been exchanged by another amino acid residue, preferably one which can be coded for by the genetic code.
• the definition also comprises the case when amino acid resi ⁇ dues are added at or deleted from the N-terminal and/or the C-terminal end of the peptide.
• the total number of such additions, deletions and exchanges does not exceed five, more preferred it does not exceed three.
• One advantage is that the absorption is slightly protracted. This is expedient because administration of the medicament can then take place as required immediately before a meal. In this way the peptide becomes available with its influence on the insulin secretion at the same time as the food arrives in the stomach. The patients need not plan their meals long time ahead and they thus experience an improved quality of life.
• formulations according to the present invention can provide a plasma concentration of the peptide which .is fairly con ⁇ stant for a period of time sufficient to cover the duration of a meal.
• formulations with tauro-24,25-dihydrofusidate, with ⁇ - cyclodextrin or with a plain phosphate buffer having a pH value of 7.4 tend to give a course of the plasma concentra ⁇ tion of the peptide which is less favourable: a very high initial peak which rather soon drops below the level obtain- able with the formulations with phospholipids.
• Examples of preferred compounds of formula II are: dioctanoyl-L- ⁇ -phosphatidylcholine, dioctyl-O-L- ⁇ -phosphatidylcholine, didecanoyl-L- ⁇ -phosphatidylcholine, didecyl-O-L- ⁇ -phosphatidylcholine, decyl-O-L- ⁇ -lysophatidylcholine, dilauroyl-L- ⁇ -phosphatidylcholine, lauroyl-L- ⁇ -lysophosphatidylcholine.
• the formulation of this invention may be liquid, e.g. adapted for administration as a spray or solid, e.g. a powder acceptable for snuffing.
• Liquid formulations such as those based on aqueous formulations, may include ancil- lary agents, for example a pH-buffering system, preferably a phosphate r citrate or acetate buffer, a preservative and an osmotic pressure controlling agent, e.g. glycerol or sodium chloride.
• Powder formulations may contain the pharmaceuti ⁇ cally active agent and the phospholipid of formula II in admixture with nasally acceptable powdery diluents or mix ⁇ tures thereof, e.g.
• cellulose or derivatives thereof for example cellulose ethers or sodium carboxymethylcellulose, starch, a long chain fatty acid or a salt thereof, e.g. alu ⁇ minum stearate, an organic polymer, e.g. of an acrylic acid derivative or inorganic vehicles, such as talc or diatoma- ceous earth.
• an organic polymer e.g. of an acrylic acid derivative or inorganic vehicles, such as talc or diatoma- ceous earth.
• Supplementary addition of water-absorbing poly- mers for example polyethylene glycol or polyvinyl pyrroli- done may be desirable to improve adhesion of the powder for ⁇ mulation to the nasal mucosa.
• Preferred liquid formulations are those in which the diluent is water.
• Such formulations may be prepared by dispersing the phospholipid in the aqueous medium containing the GLP-1 derived active agent and ancillary agents, the dispersion being conducted by any method usually employed for suspension or emulsification, e.g. ultrasonic treatment. Adjustment of the aqueous phase to neutrality (i.e. to pH in the range from about 6.5 to about 8) may be accomplished in any of the preparatory steps.
• proteases and peptidases are associated with the nasal mucosa (see R.E. Stratford and V.H.L. Lee: Int.Journ.Pharmaceutics .0 (1986), 73 - 82) it may be desirable to incorporate biocompatible protease and peptidase inhibitors into polypeptide containing formula ⁇ tions.
• the concentration to be used of the GLP-1 derived active agent in the formulations of this invention will of course depend on the particular agent chosen, on its efficacy, on a comparison of its bioavailability by nasal administration and by other routes of administration, for example injection or infusion, and on the desired frequency of administration. Such pharmacological data can routinely be obtained by j-n vivo studies designed by those skilled in the art.
• the total daily dose of the GLP-1 derived active agent to be given which i.a. depends on the particular agent and on the condition of the patient is determined by a medically skilled person.
• the total daily dose is conveni ⁇ ently administered in submultiples thereof.
• the total daily dose of a GLP-1 derived active agent to be administered nasally in the treatment of diabetes will be in the interval from 0.05 to 20 ⁇ g per kilogram of body weight.
• An exemplary mode of preparing a GLP-l(7-36) amide formulation of this invention wherein the diluent is water comprises dissolving GLP-1(7-36)amide in water optio ⁇ nally in the presence of an acid, for example hydrochloric acid.
• An aqueous solution of a preservative for example phenol, an alkyl phenol, such as cresol, or methyl p- hydroxybenzoate, is prepared separately, optionally also containing an agent rendering the solution isotonic, such as sodium chloride or glycerol.
• the preservative solution may contain a buffering agent, such as sodium phos ⁇ phate, sodium citrate, sodium acetate or TRIS (tris(hydroxy- methyl)aminomethane) and a protease inhibitor.
• a buffering agent such as sodium phos ⁇ phate, sodium citrate, sodium acetate or TRIS (tris(hydroxy- methyl)aminomethane) and a protease inhibitor.
• the resulting preservative solution is then admixed with the solution of GLP-1(7-36)amide, optionally followed by addition of a base, for example a sodium hydroxide solution, to adjust the pH value to neutrality.
• a base for example a sodium hydroxide solution
• the phospolipid of formula II may be added to the solution of GLP-1(7-36)amide as a solution or an emulsion which is prepared by dissolving or suspending the phospholipid of formula II in water and, if necessary, subjecting any suspension to an ultrasonic treatment before mixing with the GLP-1(7-36)amide solution.
• the phospholipid solution or emulsion may, if desired, con ⁇ tain the buffering agent and preservative.
• the pH value of the formulation may be readjusted to neutrality. Finally, the resulting solution is made up to the calculated volume by addition of water.
• the formulations of this invention may be used in any dosage dispensing device adapted for intranasal ad ⁇ ministration.
• the device should be constructed with a view to ascertaining optimum metering accuracy and compatibility of is constructive elements, such as container, valve and actuator with the nasal formulation and could be based on a mechanical pump system, e.g. that of a metered-dose nebuli ⁇ zer, or on a pressurized aerosol system.
• the aerosol system requires the propellant to be inert towards the formulation. Suitable propellants may be selected among such gases as fluorocarbons, hydrocarbons, nitrogen and dinitrogen oxide or mixtures thereof.
• GLP-1(7-36) amide and GLP-l(7-37) were obtained from Bachem Feinkemicalien AG (Switzerland) and Peninsula Laboratories (England), respectively.
• the concentration of GLP-1(7- 20 36)amide and GLP-l(7-37) in solution was monitored by stan ⁇ dard reversed phase HPLC employing a gradient of aceto- nitrile and 0.1% trifluoracetic acid (10-100% over 30 minutes) with UV detection at 280 nm.
• the ⁇ -cyclodextrin was dissolved in distilled water, the peptide in question was added and the solution was freeze dried.
• a solution containing 0.5 mg/ml of GLP-1(7-36)amide in the above described phospholipid vehicle and a solution con ⁇ taining 0.5 mg/ml of GLP-1(7-36) amide in a 5 mM sodium phos ⁇ phate buffer having a pH value of 7.4 were prepared.
• Formulation 1 GLP-1(7-36)amide (250 ⁇ g) was dissolved in 1 ml of the phospholipid vehicle. 100 ⁇ l of this liquid formulation was applied in each of the nostrils of the rabbits in which it was tested.
• Formulation 2 GLP-l(7-37) (250 ⁇ g) was dissolved in 1 ml of the phospholipid vehicle. 100 ⁇ l of this liquid formulation was applied in each of the nostrils of the rabbits in which it was tested.
• Formulation 3 GLP-1(7-36)amide (50 ⁇ g) was dissolved in 1 ml of the tauro-24,25-dihydrofusidate vehicle. 100 ⁇ l of this liquid formulation was applied in each of the nostrils of the rabbits in which it was tested.
• Formulation 4 GLP-1(7-36)amide (50 ⁇ g) was mixed with 100 mg of ⁇ -cyclodextrin. 20 mg of this powder formulation was applied in one nostril of each of the rabbits in which it was tested.
• Formulation 5 GLP-1(7-36)amide (50 ⁇ g) was dissolved in 1 ml of a 20 mM sodium phosphate buffer having a pH value of 7.4. 100 ⁇ l of this liquid formulation was applied in each of the nostrils of the rabbits in which it was tested.
• the liquid formulations were administered using an Eppendorf multipipette while the powder formulation was administered by cautiously blowing 20 mg thereof from a small tube into one nostril. 1,5 ml blood samples were withdrawn at the times indicated in Table 2 and the plasma concentration of the GLP-1 (7-36)amide and GLP-l(7-37) respectively was assayed by RIA as indicated under General methods.
• Table 2 shows the observed increments in the plasma concen ⁇ trations of GLP-l(7-36)amide and GLP-l(7-37) respectively as a function of time after administration of the formulations 1 to 5 at 0 minutes.
• the plasma concentrations are corrected for the basal level of GLP-1(7-36)amide .or GLP-l(7-37) respectively found in the plasma at 0 min and are expressed as percentage of the maximal plasma concentrations observed.
• the maximal plasma concentrations observed for formulations 1 to 5 were 248 pM, 377 pM, 124 pM, 143 pM and 36 pM, respectively.
• Formulation 2 GLP-l(7-37) (600 ⁇ g) was dissolved in 1 ml of the phospholipid vehicle. 100 ⁇ l of this liquid formulation was applied in nostril in each of eight rabbits.
• the formulations were administered using an Eppendorf multi- pipette.
• Table 3 shows the observed plasma concentrations of GLP-1(7- 36)amide and GLP-l(7-37) respectively in picomoles (pM) as a function of time after administration of the formulations.

Applications Claiming Priority (3)

Publications (1)

Family

ID=8092684

Family Applications (1)

Country Status (6)

Families Citing this family (38)

Family Cites Families (4)

• 1992
  • 1992-03-19 DK DK92364A patent/DK36492D0/da not_active Application Discontinuation
• 1993
  • 1993-03-18 AU AU38887/93A patent/AU3888793A/en not_active Abandoned
  • 1993-03-18 EP EP93907819A patent/EP0631504A1/en not_active Withdrawn
  • 1993-03-18 WO PCT/DK1993/000098 patent/WO1993018785A1/en not_active Application Discontinuation
  • 1993-03-18 JP JP5516181A patent/JPH07504669A/ja active Pending
• 1994
  • 1994-09-17 KR KR1019940703281A patent/KR950700754A/ko not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events